# Covalys Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/covalys-biosciences

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.covalys.com
- Total disclosed funding: $2.6M
- Latest round: Series C (Mar 16, 2006)
- Investors on record: 4

## About

Covalys Biosciences AG is an innovative company focused on developing advanced software solutions for optimizing business operations and enhancing productivity across various sectors.Covalys Biosciences AG specializes in providing software solutions for data management, analytics, and process automation. The company, based in Switzerland, has undergone strategic changes to enhance its offerings. Covalys received Series B funding of USD 2.590 mn on March 16, 2006, from investors including EVA, Novartis Venture Fund, and Vi Partners. The total amount raised by the company stands at USD 2.590 mn, which corresponds to its latest funding round. Details regarding the founder or CEO are not provided.Covalys specializes in innovative solutions aimed at optimizing business operations and enhancing productivity across various sectors. The company's primary offerings include advanced software platforms designed for data management, analytics, and process automation. These solutions cater to a diverse clientele, including small to medium-sized enterprises (SMEs) and large corporations, seeking to streamline workflows and improve decision-making capabilities. Covalys' products are particularly targeted at industries such as finance, healthcare, and supply chain management, providing tools that address critical challenges like data integration and operational efficiency. Their offerings have been deployed in markets across North America, Europe, and Asia, demonstrating a strong commitment to meeting the needs of a global customer base.Covalys generates revenue through a combination of subscription models and service agreements, primarily structured around its flagship software solutions. Clients engage in annual or multi-year subscriptions, which grant them access to the software, regular updates, and dedicated customer support. The transaction structure often includes tiered pricing plans based on the level of service and features utilized, accommodating both B2B and direct-to-consumer interactions. Additionally, partnerships with technology providers and consulting firms expand Covalys' market reach, allowing for collaborative ventures that enhance service delivery. This structured approach ensures that clients receive tailored solutions that align with their operational requirements, further solidifying Covalys' presence in the competitive technology landscape.Covalys plans to leverage its recent Series B funding to enhance its product offerings and expand into new markets. The company is currently designed to launch new software products that aim to improve operational efficiency for clients in the finance and healthcare sectors. Specific markets targeted for expansion include North America and Asia by 2025. The funding will also support the development of strategic partnerships to enhance market penetration and service delivery.

## Funding rounds

- Series C, Mar 16, 2006 — Novartis Venture Fund, BV Group, Vi Partners
- Series B, Feb 1, 2005, $2.6M — Novartis Venture Fund, Vi Partners, EVA

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series B, Series C
- EVA (https://capitalatlas.ai/funds/eva) — Series B
- BV Group (https://capitalatlas.ai/funds/bv-group) — Series C